Janina Lewkowicz

Janina Lewkowicz

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2024 in Cells
Verified
Journal Article
Open access
PDF file
AMAdrian Mor
Adrian Mor
ATAnna Tankiewicz-Kwedlo
Anna Tankiewicz-Kwedlo
MCMarianna Ciwun
Marianna Ciwun
JLJanina Lewkowicz
Janina Lewkowicz
Dariusz PawlakDariusz Pawlak
Dariusz Pawlak
This review discusses the potential of targeting the kynurenine pathway (KP) in the treatment of inflammatory diseases. The KP, responsible for the catabolism of the amino acid tryptophan (TRP), produces metabolites that regulate various physiological processes, including inflammation, cell cycle, and neurotransmission. These metabolites, although necessary to maintain immune balance, may accumulate excessively during inflammation, leading to systemic disorders. Key KP enzymes such as indoleamine 2,3-dioxygenase 1 (IDO1), indoleamine 2,3-dioxygenase 2 (IDO2), tryptophan 2,3-dioxygenase (TDO), and kynurenine 3-monooxygenase (KMO) have been considered promising therapeutic targets. It was highlighted that both inhibition and activation of these enzymes may be beneficial, depending on the specific inflammatory disorder. Several inflammatory conditions, including autoimmune diseases, for which modulation of KP activity holds therapeutic promise, have been described in detail. Preclinical studies suggest that this modulation may be an effective treatment strategy for diseases for which treatment options are currently limited. Taken together, this review highlights the importance of further research on the clinical application of KP enzyme modulation in the development of new therapeutic strategies for inflammatory diseases.

22 November 2014 in Echocardiography
Verified
Journal Article
Closed access
PDF file
MKMarta Kamińska
Marta Kamińska
BSBożena 25 Sobkowicz
Bożena 25 Sobkowicz
RSRobert Sawicki
Robert Sawicki
JLJanina Lewkowicz
Janina Lewkowicz
ATAnna Tomaszuk‐Kazberuk
Anna Tomaszuk‐Kazberuk
WMWłodzimierz J. Musiał
Włodzimierz J. Musiał

3 July 2015 in Polish Archives of Internal Medicine
Verified
Journal Article
Open access
MKMarta Kamińska
Marta Kamińska
JLJanina Lewkowicz
Janina Lewkowicz
AŁAdam Łukasiewicz
Adam Łukasiewicz
THTomasz Adam Hirnle
Tomasz Adam Hirnle
RTRobert Trzciński
Robert Trzciński
BSBożena 25 Sobkowicz
Bożena 25 Sobkowicz

21 February 2024 in Research Square
Verified
Preprint
Open access
PDF file
JLJanina Lewkowicz
Janina Lewkowicz
ATAnna Tankiewicz-Kwedlo
Anna Tankiewicz-Kwedlo
DPDariusz Pawlak
Dariusz Pawlak
MKMalgorzata Kiluk
Malgorzata Kiluk
KLKatarzyna Lagoda
Katarzyna Lagoda
IKIrina Kowalska
Irina Kowalska
Background:Due to their connection to inflammation and oxidative stress, tryptophan metabolites via the kynurenine pathway (KP) relate to important aspects of the pathophysiology of heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D). The study aimed to examine the relationship between parameters of HFpEF, measured with transesophageal echocardiography (TTE), and metabolites of the KP. Methods: One hundred and twenty subjects, 60 with T2D and 60 without, and 55 healthy controls were prospectively included in the current study. Liquid chromatography was used to quantify metabolites of KP in plasma. TTE was performed to assess the systolic and diastolic function of the left ventricle (LV). Results: Patients with T2D and HFpEF showed an increase in TRP, KYN, and AA concentrations (p=0.001, p<0.0001, p<0.0001, respectively) with a concomitant decrease in 3-HKYN (p=0.0009), and QA (p=0.0029) compared with those with HFpEF without diabetes. There were no significant differences in the morphology of the LV or left atrium, and even the parameters of LV diastolic function were comparable in both subgroups (HFpEF with T2D and HFpEF without T2D). Left ventricular global longitudinal strain (LVGLS) was significantly lower in HFpEF with T2D than in the subgroup of HFpEF patients without T2D (p=0.0026). Conclusion: Plasma levels of the kynurenine pathway metabolites were elevated in patients with HFpEF, and especially in patients with HFpEF and T2D. An increase in KP plasma metabolite concentrations were associated with LV remodeling and diastolic dysfunction.